

Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19

- Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partners
- Junshi Biosciences' first SARS-CoV-2 neutralizing antibody, expressed using Lonza's GS Xceed® Gene Expression System, entered clinical trials in China
- Track record of the GS Xceed expression system, together with Lonza's technical and regulatory expertise cited as critical enablers for this program

Quote from Jean-Christophe Hyvert, Chief Commercial Officer, Lonza:

“With dozens of commercial products launched using the GS Exceed Gene Expression System, the first clinical trial of neutralizing antibody for COVID-19 in China using our technology is a key milestone for Lonza. Coming off the back of Junshi's approval for the first Chinese anti-PD-1 therapy, Junshi is setting the standard for biologics innovation in China and by choosing GS Xceed they have laid a solid foundation for success.”

Quote from Dr. Feng Hui, Chief Operation Officer of Junshi Biosciences:

“Time to market is critical in this campaign against COVID-19. By leveraging Lonza's GS Xceed Gene Expression System, Junshi launched the first domestic antibody targeting PD-1 (Toripalimab) in China in 2018 and is now successfully advancing JS016, the first-in-class neutralizing antibody targeting SARS-CoV-2 S protein, into clinical stage in China. This powerful GS platform enabled us to fast-track CMC development from stable cell line generation to non-GMP Tox material supply to GMP clinical manufacturing.

Basel, Switzerland, 13 July 2020 – Lonza and Junshi Biosciences announced today that the first healthy volunteer has been dosed in a Phase I clinical study of JS016 at Huashan Hospital affiliated to Fudan University in China in June. JS016 is the first SARS-CoV-2 neutralizing antibody that has entered clinical trials in China and is produced using Lonza's GS Xceed Expression System. This follows on from a successful launch of the first PD-1-targeting antibody using GS Xceed last year.

At the start of the COVID-19 outbreak, Junshi Biosciences rapidly launched the research and development program focused on neutralizing antibodies using Lonza's GS Xceed expression system. Within two months, the company had completed IND enabling preclinical studies,

process development and production for GLP toxicity studies, as well as the GMP production of clinical material. Junshi Biosciences is collaborating with Eli Lilly and Company to co-develop JS016 globally, with Junshi leading clinical development in Greater China and Lilly leading clinical development in the rest of the world.

The GS Xceed Expression System is Lonza's market-leading expression technology platform that includes host cell lines, vectors, and access to optimized media and feeds, as well as comprehensive methods and processes. This robust, fully integrated, scalable system can express a diverse range of biologic drugs and has an unparalleled track record of successfully taking programs from gene through cell line construction to commercial products. Together with the technical and regulatory expertise, this expression system is expected to provide valuable support for the JS016 program by helping to improve cell line development timelines and improving yields.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

About Junshi Biosciences

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK.

The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs.

With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit: <http://junshipharma.com/en/Index.html>

About Junshi SARS-CoV-2 Antibodies

JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface spike protein receptor binding domain and can effectively block the binding of viruses to host cell surface receptor ACE2. The project is jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science.

Lonza Contact Details

Dr. Sanna Fowler

Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
sanna.fowler@lonza.com

Dirk Oehlers

Investor Relations
Lonza Group Ltd
Tel +41 79 421 1609
dirk.oehlers@lonza.com

Junshi Biosciences Contact Details

Zhi Li

Corporate Communications
Junshi Biosciences
Tel +86 21 61058800
zhi_li@junshipharma.com

IR Team

Junshi Biosciences
Tel +86 21 61058800
Info@junshipharma.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.